March 7, 2017 - The court approved the settlement and the plan of allocation and entered the order approving the motion for attorneys’ fees and expenses, and dismissing the action with prejudice.
October 20, 2016 - The court preliminarily approved the settlement.

September 23, 2016 - Parties filed a stipulation of settlement.

October 3, 2016 - Parties filed a stipulation of settlement.

June 1, 2016 - The court denied defendants' motion to dismiss.

December 15, 2015 - Defendants filed a motion to dismiss.

October 16, 2015 - The lead plaintiff filed an amended complaint.

August 17, 2015 - Lead plaintiff and lead counsel were appointed and all cases were consolidated.

July 29, 2015 - The case was transferred to the U.S. District Court for the Eastern District of Washington.

July 21, 2015 - Lead plaintiff motions were filed.

May 22, 2015 - An investor in shares of IsoRay Inc (NYSEMKT: ISR) filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by IsoRay Inc in connection with certain allegedly false and misleading statements made between May 20, 2015 and May 21, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of IsoRay Inc (NYSEMKT: ISR) common shares between May 20, 2015 and May 21, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Defendants allegedly made false and/or misleading statements regarding IsoRay Inc’s Celsium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers and that when the true details entered the market, shares of IsoRay Inc (NYSEMKT: ISR) fell $1.10 per share or over 35% to close at $2.02 per share on May 21, 2015, damaging investors.

IsoRay Inc reported that its Total Revenue declined from $5.24 million for the 12 months period that ended on June 30, 2011 to $4.22 million for the 12 months period that ended on June 30, 2014 and that its Net loss for those respective time periods increased from $2.84 million to $5.96 million.

On May 20, 2015, IsoRay Inc announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay Inc’s Cesium-131 seeds in the treatment of lung cancer. Shares of IsoRay Inc (NYSEMKT: ISR) grew from $1.48 per share on May 19, 2015, to as high as $3.79 per share on May 21, 2015.

However, on May 21, 2015, an article was published that said that “IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy” and “to make up for the inability to deliver revenue growth -- and prop up its stock price”. Shares of IsoRay Inc (NYSE: ISR) closed on May 21, 2015 at $2.02 per share.

On May 22, 2015, NYSEMKT: ISR shares declined to as low as $1.75 per share.